Evidence map›Paper›PMID 35480227›Full record

ArticleACS bio & med chem Au2022

Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity.

Ryan P McNamara, Anthony B Eason, Yijun Zhou, Rachele Bigi, Jack D Griffith, Lindsey M Costantini, Michelle A Rudek, Nicole M Anders, Blossom A Damania, Dirk P Dittmer

Open access · goldAbstract read
In one paragraph

Article in ACS bio & med chem Au, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Advances in tumor vascular growth inhibition.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ryan P McNamaraLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.
Anthony B EasonLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.
Yijun ZhouLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.
Rachele BigiLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.
Jack D GriffithLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.
Lindsey M CostantiniLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.
Michelle A RudekSidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 401 N. Broadway, Baltimore, Maryland 21205, United States.
Nicole M AndersSidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 401 N. Broadway, Baltimore, Maryland 21205, United States.
Blossom A DamaniaLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.
Dirk P DittmerLineberger Comprehensive Cancer Center and Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, 450 West Drive, Chapel Hill, North Carolina 27599-9500, United States.ORCID https://orcid.org/0000-0003-4968-5656
University of North Carolina at Chapel Hill · USJohns Hopkins University · US

Funding

Consortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7M
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Vironomics and Biostatistics CoreP01CA019014 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, NANCY JOAN RAAB-TRAUB · 1985 to 2026
$43.8M
ART Modulation of Viral Pathogenesis in Oral EpitheliaR01DE018304 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DITTMER, DIRK P · 2007 to 2025
$6.9M
Targeted Therapies for HIV-Associated Kaposi Sarcoma and LymphomaR01CA163217 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, Dirk P Dittmer · 2011 to 2026
$5.5M
HIV and substances of abuse influence exosomes and endothelial cell functionR01DA040394 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DITTMER, DIRK P · 2015 to 2019
$1.9M
R-loops at the telomere as a toxic source of genomic instabilityR01ES031635 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GRIFFITH, JACK D · 2020 to 2024
$1.7M
UPLC with Tandem MS for Sensitive Quantitative Analysis of Small MoleculesS10RR026824 · NCRR · JOHNS HOPKINS UNIVERSITY · PI RUDEK, MICHELLE A · 2010 to 2010
$429k
NCATS NIH HHS UL1 TR003098NCI NIH HHS P01 CA019014NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA163217NCI NIH HHS UM1 CA121947NCRR NIH HHS S10 RR026824NIDA NIH HHS R01 DA040394NIDCR NIH HHS R01 DE018304NIEHS NIH HHS R01 ES031635
6 · The paper itself

Abstract

Extracellular vesicles (EVs), or exosomes, play a pivotal role in tumor growth and metastasis, such as in the case of Kaposi Sarcoma. By loading tumor-derived EVs with chemotherapeutic drugs, we noted that their pro-tumor/pro-angiogenic phenotype was converted into an anti-tumor phenotype

Identifiers

PMID35480227
PMCPMC9026271
OpenAlexW4206585315

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.